Form 8-K
8-K — AETHLON MEDICAL INC
Accession: 0001683168-26-007126
Filed: 2026-09-15
Period: 2026-09-11
CIK: 0000882291
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Financial Statements and Exhibits
Documents
8-K — aethlon_8k.htm (Primary)
EX-10.1 — AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT - JAMES A. FRAKES (aethlon_ex1001.htm)
EX-10.2 — AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT - STEVEN P. LAROSA, MD (aethlon_ex1002.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — CURRENT REPORT
8-K (Primary)
Filename: aethlon_8k.htm · Sequence: 1
AETHLON MEDICAL, INC. 8-K
false
0000882291
0000882291
2026-09-11
2026-09-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 11, 2026
Aethlon
Medical, Inc.
(Exact name of registrant as specified in its
charter)
Nevada
001-37487
13-3632859
(State or other jurisdiction of
incorporation)
(Commission File Number)
(IRS Employer Identification No.)
11555
Sorrento Valley Road, Suite
203
San Diego, California
92121
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (619) 941-0360
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
AEMD
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
September 11, 2026, Aethlon Medical, Inc. (the “Company”) entered into amendments to the employment agreements of James B.
Frakes, the Company’s Chief Executive Officer and Chief Financial Officer, and Steven P. LaRosa, M.D., the Company’s Chief
Medical Officer (collectively, the “Amendments”). The Amendments provide that, if a Change in Control (as defined in the applicable
Amendment or employment agreement) is consummated and, concurrently with such consummation, the applicable executive’s employment
is terminated under circumstances entitling the executive to severance benefits under his employment agreement, the severance payments
otherwise payable in installments will instead be paid in a single lump sum. The lump sum will equal the aggregate severance payments
that otherwise would have been payable under the applicable employment agreement and will be paid on the first regular payroll date following
the applicable release effective date, subject to the terms and conditions of the applicable employment agreement.
The
Amendments also provide that, under such circumstances, the applicable health care continuation payments will be paid in a single lump
sum equal to the aggregate health care continuation payments that otherwise would have been payable for the applicable COBRA continuation
period. Once payable, the amount of such lump sum payment will be fixed and will not be reduced, terminated, forfeited, recouped or required
to be repaid as a result of the executive subsequently becoming eligible for or obtaining group health insurance coverage through a new
employer or otherwise ceasing to be eligible for COBRA continuation coverage during the applicable COBRA continuation period.
The Amendments do not
alter the amount or calculation of the applicable severance payments or health care continuation payments or the circumstances under which
the executives become eligible for severance benefits under their respective employment agreements.
The foregoing description
of the Amendments does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendments, copies
of which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01 Financial Statements
and Exhibits.
(d) Exhibits
Exhibit Number
Description
10.1
Amendment No. 2 to Executive Employment Agreement, dated September 11, 2026, by and between the Aethlon Medical, Inc. and James A. Frakes.
10.2
Amendment No. 1 to Executive Employment Agreement, dated September 11, 2026, by and between Aethlon Medical, Inc. and Steven P. LaRosa, MD.
104
Cover Page Interactive Data File (embedded within the inline XBRL Document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 15, 2026
AETHLON MEDICAL, INC.
By:
/s/ James B. Frakes
James B. Frakes
Chief Executive Officer and Chief Financial Officer
3
EX-10.1 — AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT - JAMES A. FRAKES
EX-10.1
Filename: aethlon_ex1001.htm · Sequence: 2
Exhibit 10.1
AETHLON MEDICAL, INC.
AMENDMENT NO. 2 TO
EXECUTIVE EMPLOYMENT AGREEMENT
This Amendment No. 2 to Executive Employment Agreement
(this “Amendment”) is made and entered into as of September 11, 2026 (the “Amendment Effective Date”),
by and between James B. Frakes (“Employee”) and Aethlon Medical, Inc., a Nevada corporation (the “Company”).
The Company and Employee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALS
A. The Company and Employee are parties to that certain Executive Employment Agreement dated as of December
12, 2018, as amended by Amendment No. 1 to Executive Employment Agreement effective as of November 7, 2023 (as so amended, the “Employment
Agreement”).
B. Section 13.4 of the Employment Agreement provides that the Employment Agreement may be modified or amended
in a writing signed by Employee and a duly authorized member of the Board of Directors of the Company (the “Board”).
C. The Company
and Employee desire to amend the Employment Agreement solely to provide that, if a Change in Control is consummated and Employee is required
to resign or Employee’s employment is terminated concurrently therewith under circumstances entitling Employee to Severance Benefits
under Section 8.2, the Severance Payments and health care continuation payments otherwise payable under the Employment Agreement will
be paid in single lump sums, and the lump sum health care continuation payment will not thereafter be subject to reduction, cessation,
forfeiture, recoupment or repayment based on Employee’s subsequent health coverage or COBRA eligibility.
NOW, THEREFORE, in consideration of the
mutual covenants contained herein, the Parties agree as follows:
1. Lump Sum Payment of Severance Payments in Connection with Change
in Control.
The following new Section 8.2.1(a) is hereby added to the Employment
Agreement immediately following Section 8.2.1:
“(a) Lump Sum Payment in Connection
with Change in Control. Notwithstanding the foregoing provisions of this Section 8.2.1 to the contrary, if a Change in Control is
consummated and, concurrently with such consummation, Employee is required to resign or Employee’s employment is terminated under
circumstances giving rise to Employee’s entitlement to the Severance Payments under Section 8.2, then, in lieu of paying the Severance
Payments in installments on the Company’s regular payroll schedule, the Company shall pay the Severance Payments to Employee in
a single lump sum. The amount of the lump sum payment shall equal the aggregate Severance Payments that would otherwise be payable to
Employee under Section 8.2.1. Subject to Sections 9 and 10, such lump sum payment shall be made on the first regular payroll date following
the Release Effective Date.
For purposes of this Section 8.2.1(a),
a ‘Change in Control’ means: (i) the consummation of a merger, consolidation, reorganization or other business combination
involving the Company following which the stockholders of the Company immediately prior to such transaction do not own, directly or indirectly,
more than fifty percent (50%) of the outstanding voting power of the surviving or resulting entity (or its ultimate parent entity) immediately
following such transaction; or (ii) the consummation of a sale, lease, transfer or other disposition of all or substantially all of the
assets of the Company.”
1
2. Lump Sum Payment of Health Care Continuation
Coverage Payments in Connection with Change in Control.
The following new Section 8.2.2(a) is hereby added to the Employment
Agreement immediately following Section 8.2.2:
"(a) Lump Sum Payment in Connection
with Change in Control. Notwithstanding the foregoing provisions of this Section 8.2.2 to the contrary, if a Change in Control (as defined
in Section 8.2.1(a)) is consummated and, concurrently with such consummation, Employee is required to resign or Employee’s employment
is terminated under circumstances giving rise to Employee’s entitlement to the health care continuation payments under this Section
8.2.2, then, in lieu of paying the COBRA Premiums directly to the applicable carrier over the COBRA Premium Period, or paying any Special
Cash Payment in installments, as applicable, the Company shall pay Employee a single lump sum cash payment equal to the aggregate COBRA
Premiums (or Special Cash Payment amount, as applicable) that would otherwise be payable for the entire COBRA Premium Period. Subject
to Sections 9 and 10, such lump sum payment shall be made on the first regular payroll date following the Release Effective Date, concurrently
with the lump sum payment of the Severance Payments under Section 8.2.1(a). Once payable, the amount of such lump sum payment shall be
fixed and shall not be reduced, terminated, forfeited, recouped or required to be repaid as a result of Employee subsequently becoming
eligible for or obtaining group health insurance coverage through a new employer or otherwise ceasing to be eligible for COBRA continuation
coverage during the COBRA Premium Period.”
3. No Other Changes.
Except as expressly amended by this Amendment,
the Employment Agreement remains unmodified and in full force and effect. Without limiting the foregoing, this Amendment does not alter
the amount or calculation of the Severance Payments or the health care continuation payments, or the circumstances under which Employee
becomes eligible for the Severance Benefits under Section 8.2 or the Release Requirement under Section 9 or any other benefit payable
under the Employment Agreement..
4. Section 409A.
This Amendment is intended to comply with, or
be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), and shall be interpreted
and administered consistently with that intent. Section 10 of the Employment Agreement remains in full force and effect and applies to
all payments made pursuant to this Amendment.
5. Conflicts.
In the event of any conflict between the terms
of this Amendment and the terms of the Employment Agreement, the terms of this Amendment shall control with respect to the subject matter
addressed herein.
6. Governing Law; Counterparts.
This Amendment shall be governed by the laws of
the State of California, consistent with the Employment Agreement, and may be executed in counterparts, each of which shall be deemed
an original and all of which together shall constitute one and the same instrument. Facsimile and electronic signatures shall have the
same force and effect as original signatures.
2
IN WITNESS WHEREOF, the Parties have executed
this Amendment as of the Amendment Effective Date.
AETHLON MEDICAL, INC.
By: _/s/Steven La Rosa_________________________________
Name: Steven LaRosa
Title: Chief Medical Officer
EMPLOYEE
/s/James B. Frakes_____________________________________
James B. Frakes
3
EX-10.2 — AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT - STEVEN P. LAROSA, MD
EX-10.2
Filename: aethlon_ex1002.htm · Sequence: 3
Exhibit 10.2
AETHLON MEDICAL, INC.
AMENDMENT NO. 1 TO
EXECUTIVE EMPLOYMENT AGREEMENT
This Amendment No. 1 to Executive Employment Agreement
(this “Amendment”) is made and entered into as of September 11, 2026 (the “Amendment Effective Date”),
by and between Steven P. LaRosa, MD (“Employee”) and Aethlon Medical, Inc. (the “Company”). The
Company and Employee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALS
A. The Company and Employee are parties to that certain Executive Employment Agreement dated as of January
4, 2021 (the “Agreement”).
B. Section 13.4 of the Agreement provides that the Agreement may be modified or amended in a writing signed
by a duly authorized member of the Board of Directors of the Company (the “Board”).
C. The Company and Employee desire to amend the Agreement to provide that, if a Change in Control is consummated
and Employee’s resignation is required or employment is terminated concurrently therewith under circumstances entitling Employee
to Severance Benefits under Section 8.2, the Severance Payments and health care continuation payments otherwise payable under the Agreement
will be paid in single lump sums, and the lump sum health care continuation payment will not thereafter be subject to reduction, cessation,
forfeiture, recoupment or repayment based on Employee’s subsequent health coverage or COBRA eligibility.
NOW, THEREFORE, in consideration of the
mutual covenants contained herein, the Parties agree as follows:
1. Lump Sum Payment of Severance Payments upon
Change in Control.
The following new Section 8.2.1(a) is hereby added
to the Agreement, immediately following Section 8.2.1 (Severance Payments):
“(a) Lump Sum Payment upon
Change in Control. Notwithstanding the foregoing provisions of this Section 8.2.1 to the contrary, if a Change in Control (as defined
under the Plan and referenced in Section 5) is consummated and, concurrently with such consummation, Employee is required to resign or
Employee’s employment is terminated under circumstances giving rise to Employee’s entitlement to the Severance Payments under
Section 8.2, then, in lieu of paying the Severance Payments in installments on the Company’s regular payroll schedule, the Company
shall pay the Severance Payments to Employee in a single lump sum. The amount of the lump sum payment shall equal the aggregate Severance
Payments that would otherwise be payable to Employee under Section 8.2.1. Subject to Section 10, such lump sum payment shall be made on
the Company’s first regular payroll date following the Release Effective Date.””
2. Lump Sum Payment of Health Care Continuation
Coverage Payments upon Change in Control.
The following new Section 8.2.2(a) is hereby added
to the Agreement, immediately following Section 8.2.2 (Health Care Continuation Coverage Payments):
"(a) Lump Sum Payment upon Change
in Control. Notwithstanding the foregoing provisions of this Section 8.2.2 to the contrary, if a Change in Control (as defined under the
Plan and referenced in Section 5) is consummated and, concurrently with such consummation, Employee’s employment is terminated under
circumstances giving rise to Employee’s entitlement to the health care continuation payments under this Section 8.2.2, then, in
lieu of paying the COBRA Premiums directly to the applicable carrier over the COBRA Premium Period, or paying any Special Cash Payment
in installments, as applicable, the Company shall pay Employee a single lump sum cash payment equal to the aggregate COBRA Premiums (or
Special Cash Payment amount, as applicable) that would otherwise be payable for the entire COBRA Premium Period. Subject to Section 10,
such lump sum payment shall be made on the Company’s first regular payroll date following the Release Effective Date, concurrently
with the lump sum payment of the Severance Payments under Section 8.2.1(a). Once payable, the amount of such lump sum payment shall be
fixed and shall not be reduced, terminated, forfeited, recouped or required to be repaid as a result of Employee subsequently becoming
eligible for or obtaining group health insurance coverage through a new employer or otherwise ceasing to be eligible for COBRA continuation
coverage during the COBRA Premium Period."
1
3. No Other Changes.
Except as expressly amended by this Amendment,
the Agreement remains unmodified and in full force and effect. Without limiting the foregoing, this Amendment does not alter the amount
or calculation of the Severance Payments or the health care continuation payments, the eligibility conditions for the Severance Benefits
under Section 8.2, the Release Requirement under Section 9, or the equity acceleration provisions of Section 5.
4. Section 409A.
This Amendment is intended to comply with, or
be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), and shall be interpreted
and administered consistently with that intent, including the provisions of Section 10 of the Agreement, which remain in full force and
effect and apply equally to payments made under this Amendment.
5. Conflicts.
In the event of any conflict between the terms
of this Amendment and the terms of the Agreement, the terms of this Amendment shall control with respect to the subject matter addressed
herein.
6. Governing Law; Counterparts.
This Amendment shall be governed by the laws of
the State of California, consistent with Section 13.9 of the Agreement, and may be executed in counterparts, consistent with Section 13.5
of the Agreement.
IN WITNESS WHEREOF, the Parties have executed
this Amendment as of the Amendment Effective Date.
AETHLON MEDICAL, INC.
By: /s/ James B. Frakes_________________________________
Name: James B. Frakes
Title: Chief Executive Officer and Chief Financial Officer
EMPLOYEE
/s/ Steven La Rosa____________________________________
Steven P. LaRosa, MD
2
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.3
Cover
Sep. 11, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Sep. 11, 2026
Entity File Number
001-37487
Entity Registrant Name
Aethlon
Medical, Inc.
Entity Central Index Key
0000882291
Entity Tax Identification Number
13-3632859
Entity Incorporation, State or Country Code
NV
Entity Address, Address Line One
11555
Sorrento Valley Road
Entity Address, Address Line Two
Suite
203
Entity Address, City or Town
San Diego
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
92121
City Area Code
619
Local Phone Number
941-0360
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, $0.001 par value per share
Trading Symbol
AEMD
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration